Literature DB >> 29126858

Age, Sex, and Dose Effects of Nonbenzodiazepine Hypnotics on Hip Fracture in Nursing Home Residents.

David D Dore1, Andrew R Zullo2, Vincent Mor3, Yoojin Lee3, Sarah D Berry4.   

Abstract

OBJECTIVE: The Food and Drug Administration recommends a reduced dose of nonbenzodiazepine hypnotics in women, yet little is known about the age-, sex-, and dose-specific effects of these drugs on risk of hip fracture, especially among nursing home (NH) residents. We estimated the age-, sex-, and dose-specific effects of nonbenzodiazepine hypnotics on the rate of hip fracture among NH residents. DESIGN AND
SETTING: Case-crossover study in US NHs. PARTICIPANTS: A total of 691 women and 179 men with hip fracture sampled from all US long-stay NH residents. MEASUREMENTS: Measures of patient characteristics were obtained from linked Medicare and the Minimum Data Set (2007-2008). The outcome was hospitalization for hip fracture with surgical repair. We estimated rate ratios (RRs) and 95% confidence intervals (CIs) from conditional logistic regression models for nonbenzodiazepine hypnotics (vs nonuse) comparing 0 to 29 days before hip fracture (hazard period) with 60 to 89 and 120 to 149 days before hip fracture (control periods). We stratified analyses by age, sex, and dose.
RESULTS: The average RR of hip fracture was 1.7 (95% CI 1.5-1.9) for any use. The RR of hip fracture was higher for residents aged ≥90 years vs <70 years (2.2 vs 1.3); however, the CIs overlapped. No differences in the effect of the hypnotic on risk of hip fracture were evident by sex. Point estimates for hip fracture were greater with high-dose versus low-dose hypnotics (RR 1.9 vs 1.6 for any use), but these differences were highly compatible with chance.
CONCLUSIONS: The rate of hip fracture in NH residents due to use of nonbenzodiazepine hypnotics was greater among older patients than among younger patients and, possibly, with higher doses than with lower doses. When clinicians are prescribing a nonbenzodiazepine hypnotic to any NH resident, doses of these drugs should be kept as low as possible, especially among those with advanced age.
Copyright © 2017 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nonbenzodiazepine hypnotics; case-crossover study; hip fracture; nursing home; pharmacoepidemiology

Mesh:

Substances:

Year:  2017        PMID: 29126858      PMCID: PMC5871542          DOI: 10.1016/j.jamda.2017.09.015

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  28 in total

1.  Risk factors for adverse drug events among nursing home residents.

Authors:  T S Field; J H Gurwitz; J Avorn; D McCormick; S Jain; M Eckler; M Benser; D W Bates
Journal:  Arch Intern Med       Date:  2001-07-09

2.  A comprehensive clinical assessment tool to inform policy and practice: applications of the minimum data set.

Authors:  Vincent Mor
Journal:  Med Care       Date:  2004-04       Impact factor: 2.983

3.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2015-10-08       Impact factor: 5.562

4.  Non-benzodiazepine hypnotics: do they work for insomnia?

Authors:  David Cunnington
Journal:  BMJ       Date:  2012-01-02

5.  Identification of fractures from computerized Medicare files.

Authors:  W A Ray; M R Griffin; R L Fought; M L Adams
Journal:  J Clin Epidemiol       Date:  1992-07       Impact factor: 6.437

6.  Effects of a geriatric intervention aiming to improve quality care in nursing homes on benzodiazepine use and discontinuation.

Authors:  Philipe de Souto Barreto; Maryse Lapeyre-Mestre; Philippe Cestac; Bruno Vellas; Yves Rolland
Journal:  Br J Clin Pharmacol       Date:  2016-01-08       Impact factor: 4.335

7.  Nursing home residents and enrollment in Medicare Part D.

Authors:  Becky A Briesacher; Stephen B Soumerai; Terry S Field; Hassan Fouayzi; Jerry H Gurwitz
Journal:  J Am Geriatr Soc       Date:  2009-08-21       Impact factor: 5.562

8.  Correlation Between Use of Zopiclone and Risk of Hip Fracture in Elderly Adults: A Case-Control Study in Taiwan.

Authors:  Shih-Wei Lai; Cheng-Li Lin; Wen-Chi Chen; Kuan-Fu Liao
Journal:  J Am Geriatr Soc       Date:  2015-12-11       Impact factor: 5.562

9.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

10.  Zolpidem use and risk of fracture in elderly insomnia patients.

Authors:  Dong-Yoon Kang; Soyoung Park; Chul-Woo Rhee; Ye-Jee Kim; Nam-Kyong Choi; Joongyub Lee; Byung-Joo Park
Journal:  J Prev Med Public Health       Date:  2012-07-31
View more
  4 in total

1.  Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults.

Authors:  Andrew R Zullo; Tingting Zhang; Yoojin Lee; Kevin W McConeghy; Lori A Daiello; Douglas P Kiel; Vincent Mor; Sarah D Berry
Journal:  J Am Geriatr Soc       Date:  2018-12-21       Impact factor: 5.562

2.  Predictors of Hip Fracture Despite Treatment with Bisphosphonates among Frail Older Adults.

Authors:  Andrew R Zullo; Mark N Sorial; Yoojin Lee; Christine W Lary; Douglas P Kiel; Sarah D Berry
Journal:  J Am Geriatr Soc       Date:  2019-10-03       Impact factor: 5.562

3.  Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study.

Authors:  Kathryn Richardson; Yoon K Loke; Chris Fox; Ian Maidment; Robert Howard; Nicholas Steel; Antony Arthur; Penelope J Boyd; Clare Aldus; Clive Ballard; George M Savva
Journal:  BMC Med       Date:  2020-11-24       Impact factor: 8.775

4.  Effects of anticholinergic and sedative medication use on fractures: A self-controlled design study.

Authors:  Shahar Shmuel; Virginia Pate; Marc J Pepin; Janine C Bailey; Yvonne M Golightly; Laura C Hanson; Til Stürmer; Rebecca B Naumann; Danijela Gnjidic; Jennifer L Lund
Journal:  J Am Geriatr Soc       Date:  2021-07-22       Impact factor: 5.562

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.